Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

This study is currently recruiting participants.
Verified January 2014 by Avanir Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Avanir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01584440
First received: April 23, 2012
Last updated: January 7, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2014
  Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)